Pfizer profit surges, reaffirms sales forecast for Covid-19 products
Add BT as a preferred source
PFIZER on Thursday (Jul 28) reported a 78 per cent jump in profit and reaffirmed the combined 2022 sales forecast of US$54 billion for its Covid-19 vaccine and pill, as countries rushed to sign contracts to prepare for a surge of cases in the fall season.
Shares rose 1.8 per cent in premarket trading as overall net income rose to US$9.91 billion despite a stronger US dollar, thanks to strong demand for the vaccine as well as its antiviral treatment Paxlovid.
Demand for the pill, which was used by President Joe Biden during his bout of Covid-19 infection, has picked up recently in the United States and other countries due to fresh outbreaks.
Pfizer has been banking on demand for vaccine boosters to drive up sales for the next few years.
The company and its partner BioNTech last month signed a US$3.2 billion deal with the US government for 105 million doses of their vaccine, which includes supply of retooled Omicron-adapted booster, pending regulatory clearance. REUTERS
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
TRENDING NOW
When every phone becomes a satellite phone, what happens to Asia’s telcos?
Too little, too late? Manila’s billion-dollar bid to ignite its sputtering EV industry
Japan Home closing outlets; staff say Valu$ taking over operations
Timah Partners lands S$60 million facility from lenders including UOB, RHB
